Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tak-285. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 19/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 12/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 12/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | CSK | P41240 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tak-285 SCHEMBL29355721 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| Tak-285 SCHEMBL2747238 | 0.97 | EGFR (0.95) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL20365459 | 0.95 | EGFR (0.91) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2747601 | 0.94 | EGFR (0.90) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL13226160 | 0.94 | EGFR (0.90) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| Hydrochloric Acid SCHEMBL3506802 | 0.94 | EGFR (0.88) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2749523 | 0.94 | EGFR (0.90) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2749509 | 0.92 | EGFR (0.85) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL15580309 | 0.92 | EGFR (0.84) | EGFRERBB2ERBB3ERBB4BMPR1B | |
| SCHEMBL2747525 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | claimed |
| US-20220054491-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| EP-1752457-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-03-19 | — | — | EP | claimed |
| EP-2359825-A2 | Combination drug | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | claimed |
| WO-2011040212-A1 | THERAPEUTIC AGENT FOR BRAIN TUMOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | WO | claimed |
| US-20110003805-A1 | CONCOMITANT DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | claimed |
| EP-2255830-A1 | CONCOMITANT DRUG | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | claimed |
| US-7825127-B2 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2010-11-02 | — | — | US | claimed |
| US-20100183604-A1 | PREVENTIVE/REMEDY FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-22 | — | — | US | claimed |
| WO-2010036910-A1 | HEART PROTECTION BY ADMINISTERING AN AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | OHTA YOSHIKAZU (JP) | 2010-04-01 | — | — | WO | claimed |
| EP-2163258-A1 | PREVENTIVE/REMEDY FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2010-03-17 | — | — | EP | claimed |
| US-20100008912-A1 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-14 | — | — | US | claimed |
| EP-2063895-A2 | COMBINATION DRUG | Takeda Pharmaceutical Company Limited (JP) | 2009-06-03 | — | — | EP | claimed |
| US-7507740-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | claimed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | claimed |
| US-20080214584-A1 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-04 | — | — | US | claimed |
| WO-2008044782-A2 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-17 | — | — | WO | claimed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | claimed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20100008912-A1 | COMBINATION DRUG | ERBB2, ERBB3, ERBB4 | EGFR 5/4885ERBB2 1/4885ERBB3 2/4885 |
| US-20100183604-A1 | PREVENTIVE/REMEDY FOR CANCER | CFL1, LIMK1, LIMK2 | EGFR 1324/4885ERBB2 674/4885ERBB3 1397/4885 |
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885ERBB3 6/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | EGFR 68/4885ERBB2 21/4885ERBB3 2/4885 |
| US-20080214584-A1 | Method for treating cancer | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885ERBB3 3/4885 |
| US-20110003805-A1 | CONCOMITANT DRUG | ERBB2, MTOR, ERBB4 | EGFR 6/4885ERBB2 1/4885ERBB3 4/4885 |
| US-20220054491-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885ERBB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.